Cullinan Therapeutics, Inc.
CGEM
$9.07
$0.111.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.21M | 54.02M | 50.10M | 47.73M | 44.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 208.93M | 196.92M | 187.36M | 183.30M | 170.88M |
| Operating Income | -208.93M | -196.92M | -187.36M | -183.30M | -170.88M |
| Income Before Tax | -178.62M | -167.46M | -159.61M | -158.24M | -148.42M |
| Income Tax Expenses | 117.00K | 117.00K | -14.12M | -14.12M | -14.12M |
| Earnings from Continuing Operations | -178.74 | -167.58 | -145.49 | -144.11 | -134.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 192.00K | 1.95M | 1.95M | 1.95M |
| Net Income | -178.74M | -167.38M | -143.54M | -142.16M | -132.35M |
| EBIT | -208.93M | -196.92M | -187.36M | -183.30M | -170.88M |
| EBITDA | -208.62M | -196.61M | -187.05M | -182.99M | -170.57M |
| EPS Basic | -3.10 | -3.14 | -2.88 | -3.10 | -3.14 |
| Normalized Basic EPS | -1.93 | -1.96 | -1.99 | -2.12 | -2.15 |
| EPS Diluted | -3.10 | -3.14 | -2.88 | -3.10 | -3.14 |
| Normalized Diluted EPS | -1.93 | -1.96 | -1.99 | -2.12 | -2.15 |
| Average Basic Shares Outstanding | 230.87M | 214.98M | 199.19M | 183.59M | 168.49M |
| Average Diluted Shares Outstanding | 230.87M | 214.98M | 199.19M | 183.59M | 168.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |